Testosterone to Dihydrotestosterone Ratio as a New Biomarker for an Adverse Metabolic Phenotype in the Polycystic Ovary Syndrome

被引:84
作者
Muenzker, J. [1 ]
Hofer, D. [1 ]
Trummer, C. [1 ]
Ulbing, M. [1 ]
Harger, A. [1 ]
Pieber, T. [1 ]
Owen, L. [2 ]
Keevil, B. [2 ]
Brabant, G. [3 ,4 ]
Lerchbaum, E. [1 ]
Obermayer-Pietsch, B. [1 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, A-8036 Graz, Austria
[2] Univ S Manchester Hosp, Manchester Acad Hlth Sci Ctr, Dept Clin Chem, Manchester M23 9LT, Lancs, England
[3] Univ Manchester, The Christie, Dept Endocrinol, Manchester M20 4BX, Lancs, England
[4] Med Univ Lubeck, Expt & Clin Endocrinol, Med Clin 1, D-23538 Lubeck, Germany
基金
奥地利科学基金会;
关键词
SERUM TESTOSTERONE; MASS-SPECTROMETRY; SYNDROME PCOS; WOMEN; RISK; HYPERANDROGENEMIA; IMMUNOASSAY; ENDOCRINE; OBESITY; UTILITY;
D O I
10.1210/jc.2014-2523
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Polycystic ovary syndrome (PCOS) is a heterogeneous disease with many different aspects, including hyperandrogenism and metabolic disturbances. Clinical phenotypes show different patterns of steroid hormones that have been investigated to some extent. Objective: This study intended to determine the role of the testosterone (TT) to dihydrotestosterone (DHT) ratio (TT/DHT ratio) in PCOS patients and to further assess the correlation of this ratio with hormonal, anthropometric, and metabolic parameters. Design and Setting: Serum samples of 275 premenopausal PCOS patients fulfilling Rotterdam criteria and 35 BMI-matched, premenopausal, healthy controls were analyzed for testosterone, DHT, dehydroepiandrosterone (DHEA), and androstenedione using liquid chromatography/mass spectrometry. Main Outcome Measures: We measured total levels of testosterone and DHT and calculated un-bound hormone levels as well as the ratio of testosterone to DHT. Further, impaired glucose tolerance, basal and stimulated serum insulin levels, metabolic syndrome and insulin resistance according to the homeostatic model assessment (HOMA-IR) were assessed. Results: PCOS patients showed significantly higher levels of TT (P < .001), free testosterone (P < .001), and freeDHT(P < .001) compared to healthy controls. The TT/DHT ratio was significantly higher in PCOS patients (P < .001). No difference was found for total DHT levels (P < .072). In PCOS patients alone, the TT/DHT ratio was significantly higher in obese patients (P < .001) and patients with metabolic syndrome (P < .001), impaired glucose tolerance (IGT) (P < .001) or insulin resistance (P < .001). Significant correlations of the TT/DHT ratio with various adverse anthropometric, hormonal, lipid and liver parameters and parameters of glucose metabolism were found. Conclusion: Our data provide evidence for a strong link between a high TT/DHT ratio and an adverse metabolic phenotype in PCOS patients. This correlation was only found in PCOS patients, suggesting the TT/DHT ratio to be a new biomarker for an adverse metabolic phenotype in PCOS patients.
引用
收藏
页码:653 / 660
页数:8
相关论文
共 50 条
  • [21] Defining polycystic ovary syndrome phenotype in Vietnamese women
    Ngoc Thanh Cao
    Minh Tam Le
    Vu Quoc Huy Nguyen
    Pilgrim, Justin
    Viet Nguyen Sa Le
    Dinh Duong Le
    Chi Kong Pham
    Aharon, Devora
    Hill, Micah J.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2019, 45 (11) : 2209 - 2219
  • [22] Epigenetic regulation of an adverse metabolic phenotype in polycystic ovary syndrome: the impact of the leukocyte methylation of PPARGC1A promoter
    Zhao, Hongcui
    Zhao, Yue
    Ren, Yun
    Li, Min
    Li, Tianjie
    Li, Rong
    Yu, Yang
    Qiao, Jie
    FERTILITY AND STERILITY, 2017, 107 (02) : 467 - +
  • [23] Dehydroepiandrosterone sulfate/free androgen index ratio predicts a favorable metabolic profile in patients with polycystic ovary syndrome
    Nadir, Ahmet
    Temizkan, Sule
    Ozderya, Aysenur
    Temizkan, Osman
    Orbay, Ekrem
    Aydin, Kadriye
    GYNECOLOGICAL ENDOCRINOLOGY, 2019, 35 (02) : 128 - 132
  • [24] Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome
    Bui, H. N.
    Sluss, P. M.
    Hayes, F. J.
    Blincko, S.
    Knol, D. L.
    Blankenstein, M. A.
    Heijboer, A. C.
    CLINICA CHIMICA ACTA, 2015, 450 : 227 - 232
  • [25] ANTI-MULLERIAN HORMONEAS A BIOMARKER OF METABOLIC PARAMETERS IN POLYCYSTIC OVARY SYNDROME
    Greenwood, E. A.
    FERTILITY AND STERILITY, 2018, 109 (03) : E7 - E8
  • [26] Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome
    Alpanes, Macarena
    Luque-Ramirez, Manuel
    Angeles Martinez-Garcia, M.
    Fernandez-Duran, Elena
    Alvarez-Blasco, Francisco
    Francisco Escobar-Morreale, Hector
    FERTILITY AND STERILITY, 2015, 103 (03) : 795 - U519
  • [27] The role of metabolic syndrome in the development of polycystic ovary syndrome in adolescence
    Avramenko, N. V.
    Kabachenko, O. V.
    Barkovskyi, D. Ye.
    Sierykh, K. V.
    ZAPOROZHYE MEDICAL JOURNAL, 2023, 25 (03) : 255 - 261
  • [28] Polycystic ovary syndrome and metabolic syndrome in Indigenous Australian women
    Boyle, J. A.
    Cunningham, J.
    Norman, R. J.
    Dunbar, T.
    O'Dea, K.
    INTERNAL MEDICINE JOURNAL, 2015, 45 (12) : 1247 - 1254
  • [29] Metabolic syndrome in patients with the polycystic ovary syndrome
    Panidis, Dimitrios
    Tziomalos, Konstantinos
    Papadakis, Efstathios
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (06) : 559 - 568
  • [30] The ratio of anterior anogenital distance to posterior anogenital distance: A novel-biomarker for polycystic ovary syndrome
    Simsir, Coskun
    Pekcan, Meryem Kuru
    Aksoy, Rifat Taner
    Ecemis, Tolga
    Coskun, Bugra
    Kilic, Sevtap Hamdemir
    Tokmak, Aytekin
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2019, 82 (10) : 782 - 786